Table 1.
Patient characteristics by IBC status
| Characteristic | IBC (n = 206) |
Non-IBC (n = 1298) |
P value |
|---|---|---|---|
| Age at diagnosis (years) | 0.0016 | ||
| Mean ± SD | 50.35 ± 11.73 | 53.39 ± 12.83 | |
| Median (range) | 49.5 (26–85) | 53 (17–93) | |
| Ethnicity | 0.5299 | ||
| White | 145 (70.4) | 896 (69) | |
| Black | 35 (17) | 201 (15.5) | |
| Other | 26 (12.6) | 201 (15.5) | |
| Menopausal status | 0.0022 | ||
| Postmenopausal | 102 (50.2) | 793 (61.6) | |
| Premenopausal | 101 (49.8) | 495 (38.4) | |
| Missing | 3 | 10 | |
| ECOG performance status | 0.0031 | ||
| 0 or 1 | 201 (98) | 1196 (93) | |
| > 1 | 4 (2) | 90 (7) | |
| Missing | 1 | 12 | |
| Hormone receptor status | <0.0001 | ||
| Positive | 105 (52.2) | 960 (76.4) | |
| Negative | 96 (47.8) | 297 (23.6) | |
| Missing | 5 | 41 | |
| HER2 status | 0.0200 | ||
| Positive | 70 (35.2) | 325 (27.2) | |
| Negative | 129 (64.8) | 872 (72.8) | |
| Missing | 7 | 101 | |
| Subtype | <0.0001 | ||
| HR +/HER2+ | 34 (17.3) | 215 (18) | |
| HR +/HER2− | 70 (35.5) | 692 (58.1) | |
| HR −/HER2+ | 35 (17.8) | 107 (9) | |
| HR −/HER2− | 58 (29.4) | 178 (14.9) | |
| Missing | 9 | 106 | |
| No. of metastatic sites | 0.0266 | ||
| 1 | 104 (50.5) | 762 (58.7) | |
| > 1 | 102 (49.5) | 536 (41.3) | |
| Site of metastasis | 0.0341 | ||
| Visceral | 102 (49.5) | 745 (57.4) | |
| Nonvisceral | 104 (50.5) | 553 (42.6) | |
| Chemotherapy as first-line therapya | <0.0001 | ||
| Yes | 187 (90.8) | 751 (57.9) | |
| No | 19 (9.2) | 547 (42.1) | |
| Anthracycline therapya | <0.0001 | ||
| Yes | 94 (45.6) | 353 (27.2) | |
| No | 112 (54.4) | 945 (72.8) | |
| Taxane therapya | <0.0001 | ||
| Yes | 132 (64.1) | 465 (35.8) | |
| No | 74 (35.9) | 833 (64.2) | |
| HER2-targeting therapya | 0.0007 | ||
| Yes | 46 (22.3) | 173 (13.3) | |
| No | 160 (77.7) | 1125 (86.7) | |
| Hormonal therapya | <0.0001 | ||
| Yes | 9 (4.4) | 444 (34.2) | |
| No | 197 (95.6) | 854 (65.8) | |
| Locoregional surgery | <0.0001 | ||
| Yes | 81 (39.3) | 316 (24.3) | |
| No | 125 (60.7) | 982 (75.7) |
Values in table are number of patients (percentage) unless otherwise indicated
HR hormone receptor
a
Therapy received as first-line